The Patent Finder

Terms ending in 2041

Forma Therapeutics, Inc.

Every in-force patent on Forma Therapeutics, Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,053,458Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound
In force
 · High confidence
Novo Nordisk Health Care AGIn forceHigh confidence
US 11,566,013Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH1)
In force
 · High confidence
Forma Therapeutics, Inc.In forceHigh confidence
US 11,795,168Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP)
In force
 · High confidence
Forma Therapeutics, Inc.In forceHigh confidence
US 12,454,532Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP)
In force
 · High confidence
Forma Therapeutics, Inc.In forceHigh confidence
US 12,252,490Inhibiting Deubiquitinase USP25 and USP28
In force
 · High confidence
Valo Health, Inc.In forceHigh confidence
US 12,049,466Fused Bicyclic Compounds Useful as Ubiquitin-Specific Peptidase 30 Inhibitors
In force
 · High confidence
Forma Therapeutics, Inc.In forceHigh confidence
US 11,801,243Bromodomain Inhibitors for Androgen Receptor-Driven Cancers
In force
 · High confidence
Forma Therapeutics, Inc.In forceHigh confidence
US 12,122,778Activating Pyruvate Kinase R
In force
 · Medium confidence
Novo Nordisk Health Care AGIn forceMedium confidence
8 of 8 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by Forma Therapeutics, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited